Alto Neuroscience (ANRO) Capital Expenditures (2023 - 2026)
Alto Neuroscience (ANRO) reported Capital Expenditures of $941000.0 for Q1 2026, up 3820.83% on a YoY basis from $24000.0 in Q1 2025, and up 3820.83% sequentially from $24000.0 in Q1 2025.
Alto Neuroscience (ANRO) Capital Expenditures (2023 - 2026) Analysis & Trends
Alto Neuroscience (ANRO) has 4 years of Capital Expenditures data on file, last reported at $941000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures rose 3820.83% year-over-year to $941000.0; the trailing twelve-month figure through Mar 2026 stood at $941000.0 (up 570.5% YoY), and the FY2025 full-year result was $24000.0, changed N/A from the prior year.
- Capital Expenditures advanced to $941000.0 in Q1 2026, from $24000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $941000.0 in Q1 2026 to a low of -$532000.0 in Q3 2024.
- A 4-year average of $159444.4 and a median of $75000.0 in 2023 frame the typical range for Capital Expenditures.
- Across the five-year window, Capital Expenditures tumbled 609.33% in 2024 and soared 3820.83% in 2026, its largest moves.
- Tracing ANRO's Capital Expenditures over 4 years: stood at $470000.0 in 2023, then sank by 106.81% to -$32000.0 in 2024, then soared by 175.0% to $24000.0 in 2025, then soared by 3820.83% to $941000.0 in 2026.
- Business Quant data shows ANRO's Capital Expenditures at $941000.0 in Q1 2026, $24000.0 in Q1 2025, and -$32000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Alto Neuroscience | 881.86 Mn | 881.86 Mn | - | 941,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 941,000.00 |
| Mar 31, 2026 | 941,000.00 |
| Mar 31, 2025 | 24,000.00 |
| Mar 31, 2025 | 24,000.00 |
| Dec 31, 2024 | -32,000.00 |
| Dec 31, 2024 | -32,000.00 |
| Sep 30, 2024 | -532,000.00 |
| Sep 30, 2024 | -532,000.00 |
| Jun 30, 2024 | 340,000.00 |
| Jun 30, 2024 | 340,000.00 |
| Mar 31, 2024 | 224,000.00 |
| Mar 31, 2024 | 224,000.00 |
| Dec 31, 2023 | 470,000.00 |
| Dec 31, 2023 | 470,000.00 |
| Sep 30, 2023 | -75,000.00 |
| Sep 30, 2023 | -75,000.00 |
| Jun 30, 2023 | 75,000.00 |
| Jun 30, 2023 | 75,000.00 |